Cardiovascular safety of stimulants in children: Findings from recent population-based cohort studies

Current Psychiatry Reports

Volumn 15, Issue 8, 2013, Pages

  Winterstein, Almut G ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ADHD; Attention deficit hyperactivity deficit; Cardiovascular risk; Central nervous system safety; Children; Drug safety; Pharmacoepidemiology; Psychiatry; Stimulants

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT; PEMOLINE; PSYCHOTROPIC AGENT;

ACUTE HEART INFARCTION; ADJUSTMENT DISORDER; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COHORT ANALYSIS; COLOMBIA; CONDUCT DISORDER; DEMOGRAPHY; DRUG SAFETY; DRUG USE; EMOTIONAL DISORDER; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH HAZARD; HEALTH INSURANCE; HEART INFARCTION; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL ADMISSION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAID; POPULATION RESEARCH; SAMPLE SIZE; SOCIOECONOMICS; SUDDEN CARDIAC DEATH; SYMPTOMATOLOGY; TACHYCARDIA; TIMED DRUG RELEASE; UNITED STATES; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HUMANS; UNITED STATES; YOUNG ADULT;

EID: 84880850150     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0379-y     Document Type: Article

References (19)

1. (CDC) Center for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59(44):1439-43.
2. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-8.
3. Osterweil N. FDA Pediatric advisers say nay to ADHD drug black box. MedPage Today 2006; http://www.medpagetoday.com/Psychiatry/ADHD-ADD/2921. Accessed 30 March 2013.
4. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-35.
5. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35-43. (Pubitemid 43010496)
6. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21(1):92-5. (Pubitemid 43040200)
7. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002;36(7-8):1142-9. (Pubitemid 34755788)
8. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry. 2001;40(5):525-9. (Pubitemid 32374269)
9. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826-32. (Pubitemid 32104127)
10. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2007;120(6):e1494- 1501. (Pubitemid 350223669)
11. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124(1):e75-80.
12. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102-10.
13. Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012.
14. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896-904.
15. Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627.
16. Guidance for industry: Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD2008.
17. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med. 2003;114(1):51-5. (Pubitemid 36126516)
18. El Hajjar M, Hermida JS, Caron FM, Nassif D, Bourges-Petit E, Maingourd Y. Tachycardia-induced cardiomyopathy in children: a difficult diagnosis but a reversible form of left ventricular dysfunction. Arch Pediatr. 2004;11(1):24-8. (Pubitemid 38049351)
19. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29(4):709-15. (Pubitemid 27128241)